FDA backs Astellas' Astragraf XL for kidney transplant rejection prophylaxis The Pharma Letter ... Astellas Pharma's (TYO: 4503) Astragraf XL (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab ... |
